Concepts (242)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Monoclonal Gammopathy of Undetermined Significance | 6 | 2023 | 33 | 4.480 |
Why?
|
| Multiple Myeloma | 10 | 2024 | 323 | 4.410 |
Why?
|
| Prostatic Neoplasms | 16 | 2022 | 319 | 3.120 |
Why?
|
| Lymphoma, Non-Hodgkin | 6 | 2022 | 51 | 2.050 |
Why?
|
| Biomarkers, Tumor | 6 | 2019 | 453 | 1.260 |
Why?
|
| Early Detection of Cancer | 6 | 2024 | 265 | 1.120 |
Why?
|
| SEER Program | 5 | 2024 | 65 | 1.020 |
Why?
|
| Aged | 36 | 2024 | 13334 | 0.960 |
Why?
|
| Electronic Health Records | 5 | 2023 | 352 | 0.900 |
Why?
|
| Diet | 5 | 2021 | 634 | 0.890 |
Why?
|
| Precancerous Conditions | 1 | 2023 | 72 | 0.810 |
Why?
|
| Middle Aged | 33 | 2024 | 16245 | 0.790 |
Why?
|
| Paraproteinemias | 1 | 2022 | 18 | 0.790 |
Why?
|
| Colorectal Neoplasms | 3 | 2023 | 254 | 0.770 |
Why?
|
| United States | 23 | 2024 | 7513 | 0.770 |
Why?
|
| Prostate-Specific Antigen | 3 | 2022 | 66 | 0.760 |
Why?
|
| Male | 38 | 2024 | 27545 | 0.710 |
Why?
|
| Humans | 57 | 2024 | 59416 | 0.710 |
Why?
|
| Aged, 80 and over | 17 | 2023 | 5094 | 0.700 |
Why?
|
| Healthcare Disparities | 2 | 2024 | 330 | 0.700 |
Why?
|
| Cause of Death | 3 | 2020 | 200 | 0.690 |
Why?
|
| International Classification of Diseases | 1 | 2021 | 143 | 0.690 |
Why?
|
| Case-Control Studies | 12 | 2022 | 1053 | 0.690 |
Why?
|
| Breast Neoplasms | 4 | 2022 | 1129 | 0.660 |
Why?
|
| Disease Progression | 6 | 2023 | 1045 | 0.630 |
Why?
|
| Adult | 25 | 2024 | 15759 | 0.620 |
Why?
|
| Registries | 4 | 2020 | 804 | 0.610 |
Why?
|
| Algorithms | 2 | 2021 | 990 | 0.590 |
Why?
|
| Hypertension | 1 | 2023 | 600 | 0.560 |
Why?
|
| Neoplasm Proteins | 1 | 2018 | 276 | 0.530 |
Why?
|
| Fatty Acids | 2 | 2018 | 193 | 0.510 |
Why?
|
| Risk Factors | 14 | 2022 | 5011 | 0.490 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2017 | 212 | 0.490 |
Why?
|
| Hodgkin Disease | 1 | 2015 | 56 | 0.480 |
Why?
|
| Socioeconomic Factors | 4 | 2021 | 781 | 0.440 |
Why?
|
| HIV Seronegativity | 1 | 2013 | 18 | 0.440 |
Why?
|
| Female | 23 | 2024 | 30883 | 0.440 |
Why?
|
| Population Health | 2 | 2023 | 15 | 0.410 |
Why?
|
| Cardiovascular Diseases | 1 | 2020 | 820 | 0.410 |
Why?
|
| Dietary Fats | 2 | 2017 | 204 | 0.400 |
Why?
|
| Comorbidity | 5 | 2022 | 1089 | 0.400 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 2 | 2024 | 5 | 0.390 |
Why?
|
| Risk Reduction Behavior | 1 | 2012 | 125 | 0.380 |
Why?
|
| Prospective Studies | 11 | 2020 | 3095 | 0.380 |
Why?
|
| Vitamin D | 1 | 2012 | 149 | 0.360 |
Why?
|
| Zinc | 1 | 2011 | 89 | 0.350 |
Why?
|
| Young Adult | 8 | 2024 | 4316 | 0.330 |
Why?
|
| Sweden | 4 | 2017 | 42 | 0.330 |
Why?
|
| Cytokines | 1 | 2013 | 905 | 0.330 |
Why?
|
| Tooth Loss | 2 | 2008 | 8 | 0.310 |
Why?
|
| Neoplasms | 4 | 2019 | 1244 | 0.300 |
Why?
|
| Mammography | 2 | 2022 | 272 | 0.290 |
Why?
|
| Fatty Acids, Omega-3 | 2 | 2022 | 48 | 0.290 |
Why?
|
| Polymorphism, Single Nucleotide | 4 | 2014 | 453 | 0.280 |
Why?
|
| Mass Screening | 3 | 2024 | 647 | 0.280 |
Why?
|
| Mortality | 3 | 2019 | 159 | 0.280 |
Why?
|
| Follow-Up Studies | 8 | 2022 | 2327 | 0.280 |
Why?
|
| Cohort Studies | 7 | 2017 | 2443 | 0.280 |
Why?
|
| Endoribonucleases | 2 | 2013 | 52 | 0.280 |
Why?
|
| Neoplasm Staging | 6 | 2020 | 454 | 0.270 |
Why?
|
| Fruit | 2 | 2015 | 121 | 0.270 |
Why?
|
| HIV Infections | 1 | 2013 | 920 | 0.270 |
Why?
|
| Surveys and Questionnaires | 8 | 2024 | 2594 | 0.260 |
Why?
|
| Massachusetts | 4 | 2024 | 2095 | 0.260 |
Why?
|
| Multimorbidity | 2 | 2023 | 38 | 0.260 |
Why?
|
| Puerto Rico | 3 | 2024 | 228 | 0.250 |
Why?
|
| Biomarkers | 3 | 2022 | 1198 | 0.250 |
Why?
|
| Health Services Research | 2 | 2017 | 270 | 0.250 |
Why?
|
| Databases, Factual | 3 | 2021 | 838 | 0.240 |
Why?
|
| Age Factors | 4 | 2021 | 1516 | 0.230 |
Why?
|
| Adolescent | 6 | 2024 | 5919 | 0.230 |
Why?
|
| Behavioral Risk Factor Surveillance System | 2 | 2023 | 48 | 0.220 |
Why?
|
| Proportional Hazards Models | 6 | 2017 | 673 | 0.220 |
Why?
|
| Occult Blood | 1 | 2023 | 15 | 0.210 |
Why?
|
| Lymphoma, Mantle-Cell | 1 | 2022 | 12 | 0.210 |
Why?
|
| Lymphoma, Follicular | 1 | 2022 | 15 | 0.210 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2022 | 39 | 0.200 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2022 | 65 | 0.200 |
Why?
|
| Cross-Sectional Studies | 4 | 2024 | 2473 | 0.190 |
Why?
|
| Antineoplastic Agents, Hormonal | 2 | 2020 | 30 | 0.190 |
Why?
|
| Clinical Trials as Topic | 1 | 2024 | 442 | 0.190 |
Why?
|
| Smoking | 3 | 2021 | 829 | 0.190 |
Why?
|
| Electronics | 1 | 2021 | 37 | 0.180 |
Why?
|
| Trans Fatty Acids | 1 | 2020 | 5 | 0.180 |
Why?
|
| Papillomavirus Vaccines | 1 | 2022 | 72 | 0.180 |
Why?
|
| Precision Medicine | 2 | 2019 | 103 | 0.180 |
Why?
|
| Outpatients | 1 | 2022 | 131 | 0.180 |
Why?
|
| Multiple Chronic Conditions | 1 | 2021 | 34 | 0.180 |
Why?
|
| Erythrocyte Membrane | 1 | 2020 | 24 | 0.180 |
Why?
|
| Observational Studies as Topic | 1 | 2021 | 60 | 0.180 |
Why?
|
| Pandemics | 2 | 2022 | 608 | 0.180 |
Why?
|
| Social Class | 1 | 2021 | 123 | 0.180 |
Why?
|
| Europe | 1 | 2021 | 183 | 0.180 |
Why?
|
| Hypersensitivity | 1 | 2021 | 61 | 0.180 |
Why?
|
| Kallikreins | 1 | 2020 | 9 | 0.180 |
Why?
|
| Papillomavirus Infections | 1 | 2022 | 124 | 0.180 |
Why?
|
| Antigens | 1 | 2021 | 146 | 0.170 |
Why?
|
| C-Reactive Protein | 3 | 2014 | 167 | 0.170 |
Why?
|
| Survival Analysis | 2 | 2012 | 553 | 0.170 |
Why?
|
| Disabled Persons | 1 | 2022 | 205 | 0.160 |
Why?
|
| Cystadenocarcinoma, Serous | 1 | 2019 | 12 | 0.160 |
Why?
|
| Mutation, Missense | 1 | 2010 | 178 | 0.160 |
Why?
|
| Delivery of Health Care | 3 | 2019 | 421 | 0.160 |
Why?
|
| Autoimmune Diseases | 1 | 2021 | 222 | 0.160 |
Why?
|
| Models, Statistical | 1 | 2020 | 307 | 0.160 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2019 | 68 | 0.160 |
Why?
|
| Human papillomavirus 16 | 1 | 2008 | 17 | 0.160 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2024 | 740 | 0.160 |
Why?
|
| Hospitals | 1 | 2022 | 376 | 0.160 |
Why?
|
| Prognosis | 3 | 2019 | 1572 | 0.160 |
Why?
|
| Fatty Acids, Monounsaturated | 1 | 2018 | 17 | 0.160 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2023 | 448 | 0.150 |
Why?
|
| Medicare | 1 | 2023 | 600 | 0.150 |
Why?
|
| Periodontal Diseases | 1 | 2008 | 15 | 0.150 |
Why?
|
| Periodontitis | 1 | 2008 | 16 | 0.150 |
Why?
|
| Ovarian Neoplasms | 1 | 2019 | 135 | 0.150 |
Why?
|
| Cancer Survivors | 1 | 2019 | 80 | 0.150 |
Why?
|
| Sex Factors | 1 | 2021 | 961 | 0.150 |
Why?
|
| Survival Rate | 2 | 2019 | 790 | 0.150 |
Why?
|
| Head and Neck Neoplasms | 1 | 2008 | 153 | 0.140 |
Why?
|
| Organizational Objectives | 1 | 2017 | 58 | 0.140 |
Why?
|
| Telemedicine | 1 | 2022 | 336 | 0.140 |
Why?
|
| Lymphoma | 1 | 2017 | 99 | 0.140 |
Why?
|
| Odds Ratio | 2 | 2018 | 773 | 0.140 |
Why?
|
| Dairy Products | 1 | 2017 | 27 | 0.140 |
Why?
|
| Health Personnel | 2 | 2013 | 342 | 0.140 |
Why?
|
| Milk | 1 | 2017 | 50 | 0.140 |
Why?
|
| Medical Oncology | 1 | 2017 | 56 | 0.140 |
Why?
|
| Education | 1 | 2017 | 74 | 0.140 |
Why?
|
| Predictive Value of Tests | 1 | 2019 | 1027 | 0.140 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2008 | 233 | 0.140 |
Why?
|
| Cholesterol | 1 | 2017 | 255 | 0.130 |
Why?
|
| Homes for the Aged | 1 | 2018 | 164 | 0.130 |
Why?
|
| Opioid-Related Disorders | 1 | 2023 | 465 | 0.130 |
Why?
|
| Inflammation | 2 | 2021 | 1097 | 0.130 |
Why?
|
| BRCA2 Protein | 1 | 2016 | 14 | 0.130 |
Why?
|
| Genomics | 1 | 2018 | 314 | 0.130 |
Why?
|
| Burkitt Lymphoma | 1 | 2016 | 56 | 0.130 |
Why?
|
| Connecticut | 1 | 2015 | 86 | 0.120 |
Why?
|
| Population Surveillance | 2 | 2016 | 205 | 0.120 |
Why?
|
| Meat | 1 | 2015 | 44 | 0.120 |
Why?
|
| Vasectomy | 1 | 2014 | 1 | 0.120 |
Why?
|
| Vegetables | 1 | 2015 | 91 | 0.120 |
Why?
|
| Antineoplastic Agents | 1 | 2019 | 645 | 0.110 |
Why?
|
| Herpesvirus 4, Human | 1 | 2015 | 181 | 0.110 |
Why?
|
| Emergency Service, Hospital | 1 | 2022 | 1023 | 0.110 |
Why?
|
| Veterans | 1 | 2021 | 724 | 0.110 |
Why?
|
| Homosexuality, Male | 1 | 2013 | 38 | 0.110 |
Why?
|
| Time Factors | 3 | 2012 | 3573 | 0.110 |
Why?
|
| Life Style | 1 | 2015 | 328 | 0.110 |
Why?
|
| Incidence | 4 | 2024 | 1239 | 0.110 |
Why?
|
| Prevalence | 1 | 2017 | 1284 | 0.110 |
Why?
|
| Obesity | 1 | 2021 | 1184 | 0.100 |
Why?
|
| Feeding Behavior | 1 | 2015 | 314 | 0.100 |
Why?
|
| Cholestanetriol 26-Monooxygenase | 1 | 2012 | 3 | 0.100 |
Why?
|
| Vitamin D-Binding Protein | 1 | 2012 | 4 | 0.100 |
Why?
|
| 25-Hydroxyvitamin D3 1-alpha-Hydroxylase | 1 | 2012 | 4 | 0.100 |
Why?
|
| Retinoid X Receptor alpha | 1 | 2012 | 6 | 0.100 |
Why?
|
| Vitamin D3 24-Hydroxylase | 1 | 2012 | 7 | 0.100 |
Why?
|
| Steroid Hydroxylases | 1 | 2012 | 9 | 0.100 |
Why?
|
| Genetic Association Studies | 1 | 2013 | 118 | 0.100 |
Why?
|
| Receptors, Calcitriol | 1 | 2012 | 32 | 0.100 |
Why?
|
| Nursing Homes | 1 | 2018 | 665 | 0.100 |
Why?
|
| Seasons | 1 | 2012 | 130 | 0.100 |
Why?
|
| Health Behavior | 1 | 2015 | 470 | 0.100 |
Why?
|
| Antioxidants | 1 | 2013 | 244 | 0.100 |
Why?
|
| Body Mass Index | 1 | 2015 | 885 | 0.090 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2011 | 348 | 0.080 |
Why?
|
| Genotype | 3 | 2013 | 636 | 0.080 |
Why?
|
| California | 2 | 2020 | 161 | 0.080 |
Why?
|
| Gene Expression Profiling | 1 | 2012 | 702 | 0.080 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2012 | 673 | 0.080 |
Why?
|
| Cell Membrane | 2 | 2022 | 490 | 0.070 |
Why?
|
| National Cancer Institute (U.S.) | 2 | 2017 | 33 | 0.070 |
Why?
|
| Risk Assessment | 3 | 2020 | 1911 | 0.070 |
Why?
|
| RNA, Messenger | 1 | 2012 | 1469 | 0.070 |
Why?
|
| Interleukin-6 | 2 | 2013 | 309 | 0.060 |
Why?
|
| Logistic Models | 2 | 2018 | 1252 | 0.060 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2019 | 404 | 0.060 |
Why?
|
| Trust | 1 | 2024 | 69 | 0.060 |
Why?
|
| Retrospective Studies | 3 | 2020 | 6000 | 0.050 |
Why?
|
| Genetic Testing | 1 | 2024 | 132 | 0.050 |
Why?
|
| Patient Participation | 1 | 2024 | 211 | 0.050 |
Why?
|
| Time-to-Treatment | 1 | 2022 | 100 | 0.050 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2022 | 118 | 0.050 |
Why?
|
| Life Tables | 1 | 2020 | 24 | 0.050 |
Why?
|
| Marital Status | 1 | 2020 | 43 | 0.050 |
Why?
|
| Scandinavian and Nordic Countries | 1 | 2010 | 4 | 0.040 |
Why?
|
| Genetic Variation | 2 | 2014 | 364 | 0.040 |
Why?
|
| Finland | 1 | 2010 | 20 | 0.040 |
Why?
|
| Michigan | 1 | 2020 | 39 | 0.040 |
Why?
|
| Regional Medical Programs | 1 | 2020 | 6 | 0.040 |
Why?
|
| Preventive Health Services | 1 | 2020 | 72 | 0.040 |
Why?
|
| Liquid Biopsy | 1 | 2019 | 4 | 0.040 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2020 | 77 | 0.040 |
Why?
|
| Health Plan Implementation | 1 | 2020 | 42 | 0.040 |
Why?
|
| Vaccination | 1 | 2022 | 336 | 0.040 |
Why?
|
| Advisory Committees | 1 | 2020 | 107 | 0.040 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2019 | 29 | 0.040 |
Why?
|
| Health Surveys | 1 | 2020 | 306 | 0.040 |
Why?
|
| Public Health Surveillance | 1 | 2019 | 29 | 0.040 |
Why?
|
| Colorado | 1 | 2019 | 19 | 0.040 |
Why?
|
| Washington | 1 | 2019 | 25 | 0.040 |
Why?
|
| Neoplasm Grading | 1 | 2019 | 74 | 0.040 |
Why?
|
| Regression Analysis | 1 | 2020 | 483 | 0.040 |
Why?
|
| Combined Modality Therapy | 1 | 2020 | 354 | 0.040 |
Why?
|
| Multicenter Studies as Topic | 1 | 2018 | 115 | 0.040 |
Why?
|
| Administration, Oral | 1 | 2019 | 344 | 0.040 |
Why?
|
| Analgesics, Opioid | 1 | 2023 | 495 | 0.040 |
Why?
|
| Self Report | 1 | 2020 | 366 | 0.040 |
Why?
|
| Research | 1 | 2019 | 191 | 0.040 |
Why?
|
| Guideline Adherence | 1 | 2020 | 296 | 0.040 |
Why?
|
| Data Collection | 1 | 2019 | 384 | 0.040 |
Why?
|
| Disease Management | 1 | 2019 | 220 | 0.040 |
Why?
|
| Medication Adherence | 1 | 2020 | 254 | 0.040 |
Why?
|
| Cost-Benefit Analysis | 1 | 2018 | 299 | 0.040 |
Why?
|
| Research Personnel | 1 | 2017 | 86 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2020 | 1225 | 0.030 |
Why?
|
| Mentors | 1 | 2017 | 117 | 0.030 |
Why?
|
| Kenya | 1 | 2016 | 81 | 0.030 |
Why?
|
| Tissue Array Analysis | 1 | 2016 | 29 | 0.030 |
Why?
|
| Watchful Waiting | 1 | 2016 | 24 | 0.030 |
Why?
|
| History, 21st Century | 1 | 2016 | 161 | 0.030 |
Why?
|
| Research Design | 1 | 2018 | 567 | 0.030 |
Why?
|
| Quality Improvement | 1 | 2020 | 425 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2016 | 386 | 0.030 |
Why?
|
| Biopsy | 1 | 2016 | 375 | 0.030 |
Why?
|
| Cytoplasm | 1 | 2016 | 273 | 0.030 |
Why?
|
| Immunohistochemistry | 1 | 2016 | 847 | 0.030 |
Why?
|
| Risk | 1 | 2014 | 373 | 0.030 |
Why?
|
| Androgen Antagonists | 1 | 2013 | 21 | 0.030 |
Why?
|
| Prostatectomy | 1 | 2013 | 46 | 0.030 |
Why?
|
| Prostate | 1 | 2013 | 54 | 0.030 |
Why?
|
| Cell Nucleus | 1 | 2016 | 603 | 0.020 |
Why?
|
| Molecular Epidemiology | 1 | 2011 | 26 | 0.020 |
Why?
|
| Infant | 1 | 2016 | 1523 | 0.020 |
Why?
|
| Hospital Mortality | 1 | 2016 | 846 | 0.020 |
Why?
|
| Linkage Disequilibrium | 1 | 2011 | 46 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2016 | 1838 | 0.020 |
Why?
|
| Child | 1 | 2016 | 4305 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2013 | 5171 | 0.010 |
Why?
|
| Animals | 1 | 2017 | 19640 | 0.010 |
Why?
|